Insights & news

Dutch Competition Authority Continues Excessive Pricing Probe of Leadiant

  • 29/06/2020
  • Articles

Autoriteit Consument & Markt, the Dutch competition authority (ACM), announced today that it will continue its excessive pricing probe against Leadiant. It says that it hopes to terminate the fact-finding part of its investigation after the summer.
Leadiant has come under intense regulatory, competition and media scrutiny on account of the allegedly excessive prices which it charges for chenodeoxycholic acid Leadiant (“CDCA”), a medicine indicated for the treatment of patients afflicted with cerebrotendinous xanthomatosis, a rare metabolic disorder (“CTX”) (see, Van Bael & Bellis Life Sciences News Alert of 11 February 2019, 9 April 2019, 9 September 2019, 17 September 2019 and 16 October 2019). Leadiant secured orphan medicine status for CDCA in December 2014 after it succeeded in demonstrating the significant benefit of CDCA over existing treatments of CTX. However, the list price of CDCA is much higher than that of an old medicine with the same active substance indicated for the treatment of cholesterol gallstones.
For ACM, keeping in check medicine pricing is an enforcement priority. Further competition inquiries against Leadiant are understood to be pending in at least Belgium and Italy and possibly also Spain. If the Italian authority respects its original timetable, the outcome of its inquiry should be known in the autumn.   


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 13/07/2020
    • Articles

    Competition Developments in Pharmaceutical Sector - UK Competition and Markets Authority and European Commission

    The pharmaceutical sector continues to draw competition scrutiny across Europe. United Kingdom On 9 June 2020, the Competition and Markets Authority (CMA) concluded its investigation into the supply of fludrocortisone acetate tablets (FAT), a prescription-only medicine indicated for the treatment of primary and secondary adrenal insufficiency, known as Addison’s Disease (see, attached press release). Aspen Pharma (Aspen) of South-Africa, UK based company Amilco and Dutch firm Tiofarma had apparently agreed that Aspen would be the sole supplier of FAT in the UK. Amilco and Tiofarma were promised financial compensation, while Aspen was given free rein which allegedly allowed it to abuse its monopoly position and increase its prices for FAT by up to 1,800%.

    Read more
    • 09/07/2020
    • Articles

    Court of Justice of European Union Is Asked Preliminary Questions on Application of Falsified Medicines

    Attached is a note discussing a German reference for a preliminary ruling seeking clarification from the Court of Justice of the European Union regarding the application of the Falsified Medicines Directive to parallel-traded medicines. A judgment is due in 2021.

    Read more
    • 07/07/2020
    • Articles

    European Medicines Agencies Network Strategy to 2025

    The European Medicines Agency (EMA) and the national competent authorities (NCAs) of the 27 EU Member States in addition to those of Iceland, Liechtenstein and Norway presented on 6 July 2020 a proposed network strategy for tackling healthcare challenges in a rapidly evolving environment (see, attachment). The strategy is supposed to apply until 2025 and stakeholders are invited to submit their comments in response to an online questionnaire by 4 September 2020.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *